NW-7-207

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameNW-7-207
Drug Alias NameNW-7-207
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangzhou Lupeng Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Lupeng Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A